Table 2. Interphase (N=53) and metaphase (N=25) telomere lengths according to different clinical subtypes of myelodysplastic syndrome.
| N | Mean Telomere length (SD)* | P value | |
|---|---|---|---|
| Interphase | |||
| WHO subtypes | 0.069 | ||
| RCUD | 16 | 375.17 (104.8) | |
| RARS | 2 | 627.04 (340.3) | |
| RCMD | 7 | 407.29 (141.6) | |
| RAEB-1 | 11 | 429.26 (189.6) | |
| RAEB-2 | 15 | 442.72 (195.3) | |
| MDS-U | 2 | 740.72 (295.7) | |
| IPSS | 0.689 | ||
| Low/Intermediate-1 | 30 | 415.98 (172.4) | |
| Intermediate-2 | 13 | 442.29 (198.7) | |
| High | 10 | 472.25 (195.9) | |
| Total | 53 | 433.05 (181.1) | |
| Metaphase p-arm | |||
| WHO subtypes | 0.206 | ||
| RCUD | 9 | 30,412.00 (10,926.4) | |
| RARS | 3 | 22,498.44 (8,360.9) | |
| RCMD | 2 | 17,097.14 (6,660.3) | |
| RAEB-1 | 5 | 18,495.08 (4,175.2) | |
| RAEB-2 | 4 | 35,770.56 (21,058.5) | |
| MDS-U | 2 | 21,236.93 (3,019.8) | |
| IPSS | 0.758 | ||
| Low/Intermediate-1 | 18 | 25,012.67 (10,121.7) | |
| Intermediate-2 | 4 | 28,049.30 (12,597.4) | |
| High | 3 | 30,334.45 (25,684.6) | |
| Total | 25 | 26,137.15 (12,293.9) | |
| Metaphase q-arm | |||
| WHO subtypes | 0.220 | ||
| RCUD | 9 | 29,830.84 (11,108.7) | |
| RARS | 3 | 21,841.46 (9,724.4) | |
| RCMD | 2 | 17,419.24 (5,187.5) | |
| RAEB-1 | 5 | 18,313.67 (6,355.0) | |
| RAEB-2 | 4 | 40,665.32 (27,486.7) | |
| MDS-U | 2 | 23,098.73 (681.9) | |
| IPSS | 0.475 | ||
| Low/Intermediate-1 | 18 | 24,826.89 (10,166.5) | |
| Intermediate-2 | 4 | 28,625.42 (11,547.2) | |
| High | 3 | 35,960.58 (36,252.6) | |
| Total | 25 | 26,770.70 (12,293.9) |
*Telomere/centromere fluorescence intensity ratio multiplied by 100.
Abbreviations: see Table 1.